Article

Better UCVA results, less dry eye seen in early postop period

San Diego-When compared with standard mechanical microkeratome treatments, the results following both wavefront-guided custom and standard laser treatments with the IntraLase femtosecond laser (IntraLase Corp.) were found to be statistically significantly superior in the early postoperative period.

The uncorrected visual acuity (UCVA) levels after the procedure with Alcon custom and standard treatments were better with the IntraLase compared with similar treatments with the Hansatome microkeratome (Bausch & Lomb) at all time points for visual acuity levels, and there were less dry eye findings in the eyes treated with IntraLase, Daniel S. Durrie, MD, reported at the annual meeting of the American Society of Cataract and Refractive Surgery.

In the study, 51 patients underwent Alcon CustomCornea treatment and 37 patients had standard Alcon LadarVision 4000 treatment. One eye of each patient had the LASIK flap made with the Hansatome micro keratome (Bausch & Lomb) and the other eye had the flap made with the IntraLase femtosecond laser.

The better uncorrected vision was not due to a need for a nomogram adjustment. The accuracy of the treatment was the same. One month after surgery, the mean spherical equivalent was similar in both groups. In the IntraLase eyes the average sphere was -0.14 ± 0.24 D compared with -0.26 ± 0.30 D for the Hansatome (p = 0.016) and the cylinder measurements, respectively, were -0.14 ± 0.21 D and -0.26 ± 0.27 D (p = 0.007). Six months after surgery, the spherical equivalents were -0.29 ± 0.28 D and -0.33 ± 0.32 D, respectively (p = 0.21) and the cylinder -0.19 ± 0.23 D and -0.26 ± 0.27 D (p = 0.12).

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
© 2025 MJH Life Sciences

All rights reserved.